PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AFTER ANTI-CD20 MONOCLONAL ANTIBODIES: A CASE-BASED NARRATIVE REVIEW (SIE 2026) - Oct 6, 2026 - Abstract #SP091; "The case was interpreted in light of evidence on rituximab- and obinutuzumab-associated PML, checkpoint inhibitors and virus-specific T-cell therapy...A 61-year-old woman with stage IVA follicular lym- phoma received obinutuzumab plus bendamustine, followed by maintenance obinutuzumab...Checkpoint inhibitors may help selected patients with residu- al virus-specific immunity, whereas adoptive virus-specific T-cell therapy is a promising rescue strategy for profoundly immunocompromised hosts. This case emphasizes that tim- ing is prognostically crucial: referral and lymphocyte admin- istration must be early and timely, before irreversible lesion burden and neurologic decline limit stabilization."
Clinical • Review • CNS Disorders • Hematological Disorders • Infectious Disease • Rare Diseases
|
|
M. Passucci1; C. Mancino2; G. Annechini1; G. M. D'Elia1; G. M. Assanto1; I. Del Giudice1; M. Martelli1
|